RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.
Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...
The vaccine was part of a trial involving patients who’d had surgery to remove melanoma, which can be deadly. The National ...
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from ...
MRK remains a defensive, yield-generating diversification play, but near-term upside appears constrained by valuation and ...
A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...
A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...
1don MSN
Moderna, Merck cancer vaccine data 'a great result, but not entirely unexpected', says Simon Baker
Simon Baker, Rothschild & Co Redburn global biopharma research co-head, joins 'Squawk on the Street' to discuss Moderna and ...
A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (MRNA +130.82%) and ...
1don MSN
'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancer vaccine trial
Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of ...
Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...
Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results